GlassScriptPhysician profile
Wendy Starnes
NPI 1992110761
$5,833.57
in general payments reported to CMS, 2019-2025
41 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,493 · 2022: $949 · 2023: $1,284 · 2024: $978 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,392.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $723.35 | 2021-2025 | |
| Novo Nordisk INC | $626.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $616.63 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $537.16 | 2021-2025 | |
| Lilly USA, LLC | $515.25 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $300.62 | 2021-2024 | Rexulti, Nuedexta |
| Amgen INC. | $299.33 | 2021-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.56 | 2021-2023 | |
| Pfizer INC. | $180.09 | 2021-2023 | |
| Glaxosmithkline, LLC. | $138.03 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Teva Pharmaceuticals USA, INC. | $134.09 | 2023-2025 | Austedo Xr, Austedo Xr |
| Shield Therapeutics INC | $132.40 | 2023-2024 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.20 | 2021-2024 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $120.12 | 2021-2022 | |
| Amarin Pharma, INC. | $109.58 | 2021-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Starnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.